Nevirapine Modulation of paraoxonase-1 in the Liver: An in Vitro Three-Model Approach
- PMID: 26620700
- DOI: 10.1016/j.ejps.2015.11.019
Nevirapine Modulation of paraoxonase-1 in the Liver: An in Vitro Three-Model Approach
Abstract
Introduction: Nevirapine is associated with severe hepatotoxicity, through the formation of reactive metabolites. Paraoxonase-1 (PON-1) is a promiscuous enzyme involved in the metabolism of xeno- and endobiotics and proposed as a biomarker of hepatotoxicity. The aim of this work was to explore the effects of nevirapine and its phase I metabolites, 2-hydroxy-nevirapine and 12-hydroxy-nevirapine, on PON-1 activities.
Material and methods: 2D and 3D primary cultures of rat hepatocytes, and also HepG2 2D cell cultures, were exposed to nevirapine, 2-hydroxy-nevirapine, and 12-hydroxy-nevirapine. The paraoxonase (POase), arylesterase (AREase) and lactonase (LACase) activities of PON-1 were quantified.
Results: Effects of nevirapine and its metabolites were only observed in the 3D cell model. Both nevirapine and 12-hydroxy-nevirapine increased POase (p<0.05, p<0.01) and LACase activities (p<0.05, p<0.001). The AREase activity was increased only upon 12-hydroxy-nevirapine exposure (p<0.01). These modulatory effects were observed at 300μM concentrations of nevirapine and 12-hydroxy-nevirapine.
Conclusions: The formation of 12-hydroxy-nevirapine seems to be the main factor responsible for the increase of PON-1 activities induced by nevirapine exposure. This effect was only observed in the 3D model, suggesting that an in vivo-like system is necessary for this modulation to occur. The present data suggest that the 3D model is a more suitable in vitro model than the conventional ones to explore drug effects on PON-1.
Keywords: 3D cultures; Arylesterase activity; HepG2 cell line; Lactonase activity; Nevirapine; Paraoxonase activity.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
Comparison of serum paraoxonase and arylesterase activities between iron deficiency anemia patients and chronic kidney disease patients with anemia.Ren Fail. 2016 Jun;38(5):781-6. doi: 10.3109/0886022X.2016.1162080. Epub 2016 Apr 6. Ren Fail. 2016. PMID: 27050633
-
Serum paraoxonase and arylesterase activities in metabolic syndrome in Zahedan, southeast Iran.Eur J Endocrinol. 2011 Feb;164(2):219-22. doi: 10.1530/EJE-10-0881. Epub 2010 Nov 8. Eur J Endocrinol. 2011. PMID: 21059866
-
Maternal chronic hepatitis B virus is implicated with low neonatal paraoxonase/arylesterase activities.Clin Biochem. 2008 Mar;41(4-5):282-7. doi: 10.1016/j.clinbiochem.2007.10.013. Epub 2007 Nov 7. Clin Biochem. 2008. PMID: 18035058
-
Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk.Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2803-12. doi: 10.1161/ATVBAHA.112.253930. Epub 2012 Sep 13. Arterioscler Thromb Vasc Biol. 2012. PMID: 22982463 Free PMC article.
-
Substrates for Paraoxonase.Curr Pharm Des. 2018;24(5):615-627. doi: 10.2174/1381612824666171213102310. Curr Pharm Des. 2018. PMID: 29237378 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
